Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive pulmonary disease (COPD) and entering a major licensing agreement with Telesis Bio to boost its R&D capabilities.

The AERIFY-1 trial showed itepekimab reduced moderate or severe COPD exacerbations by 27% in former smokers, marking a clinically meaningful benefit. However, the AERIFY-2 trial failed to meet its primary endpoint, raising doubts about the drug’s approval prospects and clouding investor sentiment.

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

This mixed outcome, combined with unmet high expectations for the drug’s performance, triggered a sharp sell-off, even as the broader market rose 1.7% over the same period. Analysts now question the likelihood of regulatory approval for itepekimab, with some noting that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s recent performance has lagged behind both the biotech sector and the wider market.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s strategic moves could strengthen its long-term position, but the immediate market reaction underscores investor concerns about pipeline risks and future growth.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.